Tirzepatide, an active ingredient in Eli Lilly’s diabetes and weight loss drugs, has shown promise in reducing the risk of developing type 2 diabetes in individuals with prediabetes, obesity, or overweight. In a three-year trial involving over 1,000 adults, those taking tirzepatide had a 94% lower risk of progressing to diabetes and achieved significant weight loss compared to those on a placebo. The study results were published in The New England Journal of Medicine and will be presented at ObesityWeek 2024. Tirzepatide also showed positive changes in cardiometabolic risk factors and had a consistent safety profile, with common side effects being gastrointestinal issues.
Source link
Tirzepatide Cuts Diabetes Risk By 94% In Prediabetic, Obese Individuals: Trial Results
